Exploration of peptides bound to MHC class I molecules in melanoma

Pigment Cell and Melanoma Research

Volumn 28, Issue 3, 2015, Pages 281-294

  Pritchard, Antonia L ^a   Hastie, Marcus L ^a   Neller, Michelle ^a   Gorman, Jeffrey J ^a   Schmidt, Chris W ^a   Hayward, Nicholas K ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Antigen; Epitope; Mass spectrometry; Melanoma; MHC class I; Peptide; Proteome

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; ANTIBODY; EPITOPE; HLA ANTIGEN CLASS 1; PEPTIDE; PROTEIN BINDING; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIBODY ISOLATION; ARTICLE; CANCER PATIENT; COMPARATIVE GENOMIC HYBRIDIZATION; ELUTION; EX VIVO STUDY; GENE EXPRESSION; HETEROZYGOSITY LOSS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MASS SPECTROMETRY; MELANOMA; MELANOMA CELL LINE; PATIENT; PREDICTION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN ISOLATION; PROTEIN PURIFICATION; ALGORITHM; CELL FRACTIONATION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNITY; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; PROTEIN PROCESSING; REPRODUCIBILITY; TUMOR CELL LINE;

ALGORITHMS; AMINO ACID SEQUENCE; ANTIBODIES; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; EPITOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY; MASS SPECTROMETRY; MELANOMA; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SUBCELLULAR FRACTIONS;

EID: 84927040395     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12357     Document Type: Article

References (41)

1. Almeida, L.G., et al. (2009). CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 37, D816-819.
2. Ben Dror, L., Barnea, E., Beer, I., Mann, M., and Admon, A. (2010). The HLA-B*2705 peptidome. Arthritis Rheum. 62, 420-429.
3. Braud, V., Jones, E.Y., and Mcmichael, A. (1997). The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 27, 1164-1169.
4. Cox, A.L., Skipper, J., Chen, Y., Henderson, R.A., Darrow, T.L., Shabanowitz, J., Engelhard, V.H., Hunt, D.F., and Slingluff, C.L. Jr (1994). Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716-719.
5. Crooks, G.E., Hon, G., Chandonia, J.M., and Brenner, S.E. (2004). WebLogo: a sequence logo generator. Genome Res. 14, 1188-1190.
6. De Ruiter, G.A., Smid, P., Schols, H.A., Van Boom, J.H., and Rombouts, F.M. (1992). Detection of fungal carbohydrate antigens by high-performance immunoaffinity chromatography using a protein A column with covalently linked immunoglobulin G. J. Chromatogr. 584, 69-75.
7. Engelhard, V.H., Brickner, A.G., and Zarling, A.L. (2002). Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. Mol. Immunol. 39, 127-137.
8. Fortier, M.H., Caron, E., Hardy, M.P., Voisin, G., Lemieux, S., Perreault, C., and Thibault, P. (2008). The MHC class I peptide repertoire is molded by the transcriptome. J. Exp. Med. 205, 595-610.
9. Hassan, C., Kester, M.G., De Ru, A.H., Hombrink, P., Drijfhout, J.W., Nijveen, H., Leunissen, J.A., Heemskerk, M.H., Falkenburg, J.H., and Van Veelen, P.A. (2013). The human leukocyte antigen-presented ligandome of B lymphocytes. Mol. Cell Proteomics 12, 1829-1843.
10. Hoof, I., Van Baarle, D., Hildebrand, W.H., and Kesmir, C. (2012). Proteome sampling by the HLA class I antigen processing pathway. PLoS Comput. Biol. 8, e1002517.
11. Jarmalavicius, S., Welte, Y., and Walden, P. (2012). High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells. J. Biol. Chem. 287, 33401-33411.
12. Lampen, M.H., Hassan, C., Sluijter, M., Geluk, A., Dijkman, K., Tjon, J.M., De Ru, A.H., Van Der Burg, S.H., Van Veelen, P.A., and Van Hall, T. (2013). Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Mol. Immunol. 53, 126-131.
13. Larsen, M.V., Lundegaard, C., Lamberth, K., Buus, S., Brunak, S., Lund, O., and Nielsen, M. (2005). An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur. J. Immunol. 35, 2295-2303.
14. Lennerz, V., Fatho, M., Gentilini, C., Frye, R.A., Lifke, A., Ferel, D., Wolfel, C., Huber, C., and Wolfel, T. (2005). The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. U. S. A. 102, 16013-16018.
15. Maiers, M., Gragert, L., and Klitz, W. (2007). High-resolution HLA alleles and haplotypes in the United States population. Hum. Immunol. 68, 779-788.
16. Mester, G., Hoffmann, V., and Stevanovic, S. (2011). Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. Cell. Mol. Life Sci. 68, 1521-1532.
17. Mishra, G.R., Suresh, M., Kumaran, K. et al. (2006). Human protein reference database-2006 update. Nucleic Acids Res. 34, D411-D414.
18. Mommen, G.P., Frese, C.K., Meiring, H.D., Van Gaans-Van Den Brink, J., De Jong, A.P., Van Els, C.A., and Heck, A.J. (2014). Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD). Proc. Natl Acad. Sci. U. S. A. 111, 4507-4512.
19. Nagaraj, N., Wisniewski, J.R., Geiger, T., Cox, J., Kircher, M., Kelso, J., Paabo, S., and Mann, M. (2011). Deep proteome and transcriptome mapping of a human cancer cell line. Mol. Syst. Biol. 7, 548.
20. Oliveros, J.C. (2007). VENNY. An interactive tool for comparing lists with Venn Diagrams. http://bioinfogp.cnb.csic.es/tools/venny/index.html
21. O'rourke, M.G., Johnson, M., Lanagan, C. et al. (2003). Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. 52, 387-395.
22. O'rourke, M.G., Johnson, M.K., Lanagan, C.M. et al. (2007). Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res. 17, 316-322.
23. Paul, S., Weiskopf, D., Angelo, M.A., Sidney, J., Peters, B., and Sette, A. (2013). HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J. Immunol. 191, 5831-5839.
24. Pavey, S., Johansson, P., Packer, L. et al. (2004). Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23, 4060-4067.
25. Peters, B., Bui, H.H., Frankild, S. et al. (2006). A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput. Biol. 2, e65.
26. Purcell, A.W. (2004). Isolation and characterization of naturally processed MHC-bound peptides from the surface of antigen-presenting cells. Methods Mol. Biol. 251, 291-306.
27. Purcell, A.W., and Gorman, J.J. (2004). Immunoproteomics: mass spectrometry-based methods to study the targets of the immune response. Mol. Cell Proteomics 3, 193-208.
28. Rammensee, H., Bachmann, J., Emmerich, N.P., Bachor, O.A., and Stevanovic, S. (1999). SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219.
29. Reche, P.A., and Reinherz, E.L. (2007). Prediction of peptide-MHC binding using profiles. Methods Mol. Biol. 409, 185-200.
30. Schirle, M., Keilholz, W., Weber, B., Gouttefangeas, C., Dumrese, T., Becker, H.D., Stevanovic, S., and Rammensee, H.G. (2000). Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur. J. Immunol. 30, 2216-2225.
31. Sidney, J., Peters, B., Frahm, N., Brander, C., and Sette, A. (2008). HLA class I supertypes: a revised and updated classification. BMC Immunol. 9, 1.
32. Skipper, J.C., Hendrickson, R.C., Gulden, P.H. et al. (1996). An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183, 527-534.
33. Stark, M., and Hayward, N. (2007). Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 67, 2632-2642.
34. Stark, M.S., Woods, S.L., Gartside, M.G. et al. (2012). Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 44, 165-169.
35. Tan, C.T., Croft, N.P., Dudek, N.L., Williamson, N.A., and Purcell, A.W. (2011). Direct quantitation of MHC-bound peptide epitopes by selected reaction monitoring. Proteomics 11, 2336-2340.
36. Trost, B., Bickis, M., and Kusalik, A. (2007). Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools. Immunome Res. 3, 5.
37. Vigneron, N., and Van Den Eynde, B.J. (2011). Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes. Cell. Mol. Life Sci. 68, 1503-1520.
38. Vigneron, N., Stroobant, V., Van Den Eynde, B.J., and Van Der Bruggen, P. (2013). Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun. 13, 15.
39. Vita, R., Zarebski, L., Greenbaum, J.A., Emami, H., Hoof, I., Salimi, N., Damle, R., Sette, A., and Peters, B. (2010). The immune epitope database 2.0. Nucleic Acids Res. 38, D854-D862.
40. Yewdell, J.W., and Bennink, J.R. (1999). Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51-88.
41. Yu, K., Petrovsky, N., Schonbach, C., Koh, J.Y., and Brusic, V. (2002). Methods for prediction of peptide binding to MHC molecules: a comparative study. Mol. Med. 8, 137-148.